DNA methylation in thyroid cancer
Por:
Zafon, C, Gil, J, Perez-Gonzalez, B and Jorda, M
Publicada:
1 jul 2019
Resumen:
In recent years, cancer genomics has provided new insights into genetic alterations and signaling pathways involved in thyroid cancer. However, the picture of the molecular landscape is not yet complete. DNA methylation, the most widely studied epigenetic mechanism, is altered in thyroid cancer. Recent technological advances have allowed the identification of novel differentially methylated regions, methylation signatures and potential biomarkers. However, despite recent progress in cataloging methylation alterations in thyroid cancer, many questions remain unanswered. The aim of this review is to comprehensively examine the current knowledge on DNA methylation in thyroid cancer and discuss its potential clinical applications. After providing a general overview of DNA methylation and its dysregulation in cancer, we carefully describe the aberrant methylation changes in thyroid cancer and relate them to methylation patterns, global hypomethylation and gene-specific alterations. We hope this review helps to accelerate the use of the diagnostic, prognostic and therapeutic potential of DNA methylation for the benefit of thyroid cancer patients.
Filiaciones:
Zafon, C:
Univ Hosp Vall dHebron, Diabet & Metab Res Unit VHIR, Barcelona, Spain
Univ Hosp Vall dHebron, Dept Endocrinol, Barcelona, Spain
Autonomous Univ Barcelona, Barcelona, Spain
Consortium Study Thyroid Canc CECaT, Catalonia, Spain
:
Germans Trias & Pujol Res Inst PMPPC IGTP, Program Predict & Personalized Med Canc, Barcelona, Spain
Perez-Gonzalez, B:
Germans Trias & Pujol Res Inst PMPPC IGTP, Program Predict & Personalized Med Canc, Barcelona, Spain
:
Consortium Study Thyroid Canc CECaT, Catalonia, Spain
Germans Trias & Pujol Res Inst PMPPC IGTP, Program Predict & Personalized Med Canc, Barcelona, Spain
Bronze
|